B. Schenkel

发表

The value to patients of reducing lesion severity in plaque psoriasis

A. Hauber, J. Lofland, J. González, 2011, The Journal of dermatological treatment.

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

S. Feldman, A. Kimball, J. Ortonne, 2010, Journal of the American Academy of Dermatology.

Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.

Michael Jones, B. Schenkel, Julie Just, 2005, International journal of cardiology.

Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan.

T. Tsai, Ting-Shun Wang, C. Tang, 2011, Journal of dermatological science.

Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary ☆

S. Feldman, Chenglong Han, B. Randazzo, 2016 .

Impact of ustekinumab on health‐related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

C. Han, Y. Poulin, L. Guenther, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Impact of ustekinumab on health‐related quality of life in Japanese patients with moderate‐to‐severe plaque psoriasis: Results from a randomized, double‐blind, placebo‐controlled phase 2 / 3 trial

H. Nakagawa, A. Igarashi, Takeshi Kato, 2012, The Journal of dermatology.

Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

A. Kimball, K. Papp, K. Gordon, 2012, The British journal of dermatology.

Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece

A. Petridis, D. Sotiriadis, G. Avgerinou, 2012, BMC Dermatology.

Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.

N. Shear, Ruth E. Brown, F. Pan, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic and clinical benefits of ustekinumab in the treatment of moderate to severe psoriasis in Greece

A. Petridis, D. Sotiriadis, H. Kousoulakou, 2010 .

Effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia.

T. Littlewood, B. Schenkel, M. Liss, 2005, The oncologist.

A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis

T. Brown, C. Ellis, C. Carter, 2015, The Journal of dermatological treatment.

Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis

C. Carter, Z. Cao, B. Schenkel, 2015, The Journal of dermatological treatment.

Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives – an update

M. Mascelli, Honghui Zhou, M. Plotnick, 2012, Annals of the New York Academy of Sciences.

Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide

L. Mileshkin, H. Prince, B. Schenkel, 2007, Leukemia.

Epoetin alfa improves quality of life in patients with cancer

L. Fallowfield, Michael Jones, B. Schenkel, 2004, Cancer.

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial

M. Lebwohl, K. Papp, Chenglong Han, 2010, The British journal of dermatology.

An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma

L. Mileshkin, H. Prince, B. Schenkel, 2007, Leukemia & lymphoma.

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

S. Feldman, M. Augustin, P. Szapary, 2011, The Journal of dermatological treatment.

Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.

L. Ibels, M. Zagari, Michael Jones, 2004, Kidney international.

Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis.

J. G. Vásquez, N. Bhatia, B. Schenkel, 2023, The Journal of dermatological treatment.

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma

N. Robert, J. Weber, S. Kotapati, 2022, Cancer medicine.

Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives

M. Mascelli, Honghui Zhou, M. Plotnick, 2011, Annals of the New York Academy of Sciences.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

A. Gottlieb, A. Blauvelt, D. Amato, 2013, Journal of drugs in dermatology : JDD.

Shared decision-making tools for patients with hematologic malignancies.

T. Leblanc, D. Rizzieri, Peter W. Martin, 2016 .

Development of an Online Patient Decision Aid for Previously Treated Mantle Cell Lymphoma

T. Leblanc, E. Neylon, R. Wolf, 2015 .

Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis.

Chenglong Han, J. Lofland, N. Zhao, 2011, Journal of drugs in dermatology : JDD.

Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2

K. Reich, M. Augustin, L. Guenther, 2011, The Journal of dermatological treatment.

Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan

K. Fahrbach, A. Igarashi, Hiroyo Kuwabara, 2013, The Journal of dermatological treatment.

Sa1211 Assessment of Sleep Impairment in Patients With Crohn's Disease: Results From the Ustekinumab Certifi Study

C. Han, C. Gasink, B. Schenkel, 2013 .

PSY6 USTEKINUMAB IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN OVERALL HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PSORIASIS PATIENTS

A. Kimball, R. Langley, Y. Wang, 2009 .